TSRO Key Stats
- Was 2013 the Beginning or the End for Opko Health? Fool Dec 10
- TESARO's CEO Presents at Deutsche Bank BioFEST Conference (Transcript) Seeking Alpha Dec 3
- TESARO to Present at the 2013 Deutsche Bank BioFEST Conference noodls Nov 25
- TESARO, INC. Files SEC form 10-Q, Quarterly Report Nov 8
- TESARO's CEO Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Nov 7
- TESARO Announces Third-Quarter 2013 Operating Results noodls Nov 7
- TESARO, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits Nov 7
- Q3 2013 TESARO Inc Earnings Release - After Market Close Nov 7
- TESARO's CEO Presents at Morgan Stanley Healthcare Conference (Transcript) Seeking Alpha Sep 11
- TESARO, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits Aug 30
TSRO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Tesaro is up 125.0% over the last year vs S&P 500 Total Return up 29.87%, Biomarin Pharmaceutical up 47.02%, and Clovis Oncology up 241.4%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for TSRO
Pro Report PDF for TSRO
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download TSRO Pro Report PDF
Pro Strategies Featuring TSRO
Did Tesaro make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.